CII Webinars
Upcoming
-
Thursday, April 2, 2026 · 11:00 AM EDTSponsored by Certara
As antibody–drug conjugates (ADCs) transition from late-stage development to approval and commercialization, modeling and simulation play an increasingly strategic role—shaping labeling decisions, enabling global regul... -
Wednesday, May 13, 2026 · 2:00 PM EDTSponsored by Berkeley Life
Midlife is one of the most pivotal transitions in a woman’s health journey. As women enter perimenopause and menopause, changes in hormones can significantly impact vascular function, metabolism, cognitive perfor... -
Friday, December 18, 2026 · 12:00 PM ESTSponsored by UBC & SymetryML
The rare disease registry landscape consists of small, disjointed data sets stored across different national registries and localized consortia. These data silos, coupled with strict data privacy regulations, l...
On-demand
-
Tuesday, March 17, 2026 · 11:00 AM EDTSponsored by Certara
In antibody–drug conjugate (ADC) development, identifying an initial dose is only the beginning. Long-term success depends on optimizing dose regimens that balance efficacy, safety, and regulatory expectations as progr... -
Wednesday, March 11, 2026 · 11:00 AM EDTSponsored by Novalix
For too long, DNA-encoded libraries (DEL) have been viewed primarily as a number game. At Novalix, we take a different approach: DEL screening is a powerful way to identify valuable drug-like hits, amenable for optimiz... -
Tuesday, February 17, 2026 · 11:00 AM ESTSponsored by Certara
Building regulatory-ready, defensible FIH packages for ADC programs
Antibody drug conjugates (ADCs) present distinct challenges in first-in-human (FIH) dose selection due to their structural complexity, narrow ... -
Thursday, January 29, 2026 · 1:00 PM ESTSponsored by Truveta
Traditional clinical trials are slow and costly, often hindered by delays, amendments, and recruitment challenges. As sponsors face mounting pressure to conduct faster, more inclusive studies, real-world data (RWD) is ... -
Wednesday, December 3, 2025 · 11:00 AM ESTSponsored by The Akkermansia Company
Metabolic diseases such as obesity and type-II diabetes (T2D) affect a significant number of American adults. Its prevalence over this past two decades has continued to increase, making metabolic healt... -
Tuesday, December 2, 2025 · 11:00 AM ESTSponsored by Certara
Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) increasingly expect pharmacometric evidence to play a pivotal role in New Drug Application (NDA) and Biologics... -
Thursday, July 17, 2025 · 11:00 AM EDTSponsored by Certara
Model-Based Meta-Analysis (MBMA) is a powerful quantitative tool that integrates data from publicly available clinical trial data to enable deeper insights, smarter decisions, and more efficient drug development. By co... -
Tuesday, June 17, 2025 · 11:00 AM EDTSponsored by Slope
As clinical trials become increasingly complex, and as ICH E6(R3) calls for more robust regulation of the systems and processes that dictate biospecimen operations, the need for efficient, accurate, and connected requisi... -
Thursday, April 3, 2025 · 11:00 AM EDTSponsored by Certara
Model-Informed Drug Development (MIDD) has revolutionized the pharmaceutical industry by turning complex data into actionable insights. From in silico simulations of pharmacokinetics (PK) and pharmacodynamics (P... -
Wednesday, March 19, 2025 · 11:00 AM EDTSponsored by Revvity Signals
In the realm of contemporary drug discovery, many pharmaceutical and biotech companies (Sponsors) outsource various aspects of drug development to external partners such as Contract Research Organizations (CROs... -
Wednesday, February 19, 2025 · 11:00 AM ESTSponsored by ClinEco and SCOPE Summit
This webinar is ‘Part 2’ in an ongoing conversation that took place at SCOPE Europe (Oct 2023), SCOPE US (Feb 2024), and this year’s keynote panel at SCOPE Europe 2024 in Barcelona in October. We under... -
Tuesday, October 22, 2024 · 11:00 AM EDTSponsored by Genovac, ENPICOM, and Carterra
In Part I of this webinar, we will describe discovery of therapeutic, diagnostic, and tool antibody candidates against the Receptor for Advanced Glycation End products (RAGE) in mouse, rat, and r...
